PHARMASYNTHESE was granted several CEPs by the European Health Agency for its active ingredients:
|R1-CEP 2016-312-Rev 00
|R1-CEP 2007-117-Rev 00
|R0-CEP 2015-157-Rev 02
|R0-CEP 2015-066-Rev 01
4 APIs are registered into the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and obtained Drug Master File to address Japanese pharmaceutical market.
Audits are conducted on a monthly basis by worldwide pharmaceutical companies.
INABATA France implemented the Good Distribution Practices (GDP) for the distribution of Active Pharmaceutic Ingredients.
We are supplying Pharmaceutical and Cosmetic ingredients in Europe, Japan and the rest of the world.
Every year, an important part of the profits is reinvested into various areas of our production site to upgrade the facility in terms of GMP, EHS and productivity.